{
    "id": 3209,
    "fullName": "ESR1 E380Q",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 (ER alpha) E380Q lies within the ligand-binding domain of the Esr1 (Er alpha) protein (UniProt.org, PMID: 10733896). E380Q results in activation of the Esr1 (Er alpha) protein and downstream signaling (PMID: 8114756).",
            "references": [
                {
                    "id": 1932,
                    "pubMedId": 8114756,
                    "title": "Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8114756"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1931,
                    "pubMedId": 10733896,
                    "title": "Estrogen receptors: how do they control reproductive and nonreproductive functions?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10733896"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "E380Q",
    "createDate": "02/18/2015",
    "updateDate": "07/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 112001,
        "transcript": "NM_000125",
        "gDna": "chr6:g.152011697G>C",
        "cDna": "c.1138G>C",
        "protein": "p.E380Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10220,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0810 inhibited growth of breast cancer cells expressing ESR1 E380Q in culture (PMID: 27986707).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 5424,
                "therapyName": "RU58668",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited ESR1 activity and proliferation of breast cancer cells expressing ESR1 E380Q in culture, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10204,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 inhibited growth of breast cancer cells expressing ESR1 E380Q in culture, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and H3B-5942 demonstrated synergy in an ESR1 (ER alpha)-positive breast cancer cell line expressing ESR1 E380Q, resulting in decreased proliferation in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 8022,
                "therapyName": "H3B-5942 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20699,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with ER/PR-positive metastatic breast cancer progressed while being treated with Femara (letrozole) and was subsequently found to have acquired ESR1 E380Q (PMID: 31877464).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18002,
                    "pubMedId": 31877464,
                    "title": "Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31877464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0810 inhibited growth of breast cancer cells expressing ESR1 E380Q in culture (PMID: 27986707).",
            "molecularProfile": {
                "id": 3032,
                "profileName": "ESR1 E380Q"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10855,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BETd-246 induced degradation of BET proteins, resulted in tumor regression in patient-derived xenograft models of treatment-resistant, PGR-negative, ERBB2 (HER2)-negative breast cancer harboring ESR1 E380Q (PMID: 28209615).",
            "molecularProfile": {
                "id": 27813,
                "profileName": "ERBB2 neg ESR1 E380Q PGR neg"
            },
            "therapy": {
                "id": 5603,
                "therapyName": "BETd-246",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8792,
                    "pubMedId": 28209615,
                    "title": "Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28209615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21235,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) did not inhibit tumor growth in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21237,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) treatment resulted in significant tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21236,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) treatment resulted in partial tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21238,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) and Afinitor (everolimus) combination treatment resulted in enhanced tumor growth inhibition compared to single agent treatment in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 9643,
                "therapyName": "Elacestrant + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3032,
            "profileName": "ESR1 E380Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27813,
            "profileName": "ERBB2 neg ESR1 E380Q PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35881,
            "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 111991,
            "transcript": "NM_001122742",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111996,
            "transcript": "XM_011535545",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111995,
            "transcript": "XM_017010379",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111990,
            "transcript": "XM_011535543",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111993,
            "transcript": "XM_011535547",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111997,
            "transcript": "NM_001122741",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112001,
            "transcript": "NM_000125",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111999,
            "transcript": "XM_011535544",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111994,
            "transcript": "XM_017010378",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111989,
            "transcript": "XM_017010380",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111988,
            "transcript": "XM_017010376",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111992,
            "transcript": "XM_006715374",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111987,
            "transcript": "XM_017010377",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112000,
            "transcript": "NM_001122740",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111998,
            "transcript": "XM_017010381",
            "gDna": "chr6:g.152011697G>C",
            "cDna": "c.1138G>C",
            "protein": "p.E380Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}